Amgen

Phone: +18054471000

E-mail: accountspayableinquiry@amgen.com, privacy@amgen.com

Web: https://www.amgen.com

Formerly	Applied Molecular Genetics (1980–1983)
Type	Public
Traded as	Nasdaq: AMGN NASDAQ-100 component DJIA component S&P 100 component S&P 500 component
ISIN
Industry	Biotechnology
Founded	April 8, 1980 (1980-04-08)
Headquarters	Thousand Oaks, California, U.S.
Key people	Robert A. Bradway (Chairman, President, & CEO)
Products	Aimovig, Aranesp, Blincyto, Epogen, Kineret, Enbrel, Kyprolis, Neulasta, Neupogen, Nplate, Parsabiv, Prolia, Repatha, Sensipar/Mimpara, Vectibix, Xgeva
Revenue	US$25.424 billion (2020)
Operating income	US$9.672 billion (2019)
Net income	US$7.842 billion (2019)
Total assets	US$59.707 billion (2019)
Total equity	US$9.675 billion (2019)
Number of employees	22,000 (February 2020)
Website	amgen.com

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.

For detailed contact information visit location pages below.